Guidelines for the Prophylaxis of Pneumocystis jirovecii Pneumonia (PJP) in Children with Solid Tumors

Journal of Pediatric Hematology/Oncology

Volumn 39, Issue 3, 2017, Pages 194-202

  Proudfoot, Rebecca ^a   Phillips, Bob ^b   Wilne, Sophie ^c  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF YORK   (United Kingdom)

^c QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

oncology; Pneumocystis carinii; Pneumocystis jirovecii; prophylaxis

Indexed keywords

ATOVAQUONE; CORTICOSTEROID; COTRIMOXAZOLE; DAPSONE; IMMUNOMODULATING AGENT; METHOTREXATE; PENTAMIDINE; RITUXIMAB; SULFAMETHOXAZOLE; TRIMETHOPRIM;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIMICROBIAL THERAPY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CHOLESTATIC HEPATITIS; CLINICAL OUTCOME; COUGHING; DERMATITIS; DIARRHEA; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; ELECTROLYTE DISTURBANCE; FEVER; GASTROINTESTINAL SYMPTOM; HEADACHE; HEMOLYTIC ANEMIA; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPOGLYCEMIA; HYPOTENSION; HYPOXEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; LEUKOPENIA; META ANALYSIS (TOPIC); METHEMOGLOBINEMIA; MORTALITY RATE; NEPHROTOXICITY; PATIENT RISK; PHOTOSENSITIVITY; PNEUMOCYSTIS PNEUMONIA; PNEUMOCYSTOSIS; PROPHYLAXIS; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RETROSPECTIVE STUDY; SOLID TUMOR; STANDARDIZATION; STEVENS JOHNSON SYNDROME; SYSTEMATIC REVIEW (TOPIC); TACHYPNEA; THROMBOCYTOPENIA; URTICARIA; WHEEZING; ANTIBIOTIC PROPHYLAXIS; CHILD; COMPLICATION; MICROBIOLOGY; NEOPLASMS; PNEUMOCYSTIS CARINII; PNEUMONIA, PNEUMOCYSTIS; PRACTICE GUIDELINE; PROCEDURES;

ANTIBIOTIC PROPHYLAXIS; CHILD; HUMANS; NEOPLASMS; PNEUMOCYSTIS CARINII; PNEUMONIA, PNEUMOCYSTIS; PRACTICE GUIDELINES AS TOPIC; TRIMETHOPRIM, SULFAMETHOXAZOLE DRUG COMBINATION;

EID: 85014544929     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0000000000000771     Document Type: Article

References (74)

1. Edman JC, Kovacs JA, Masur H, et al. Ribosomal RNA sequence shows Pneumocystis carinii to be a member of the fungi. Nature. 1988;334:519-522.
2. Vargas SL, Hughes WT, Santolaya ME, et al. Search for primary infection by Pneumocystis carinii in a cohort of normal, healthy infants. Clin Infect Dis. 2001;32:855-861.
3. Pifer LL, Hughes WT, Stagno S, Woods D. Pneumocystis carinii infection: evidence for high prevalence in normal and immunosuppressed children. Pediatrics. 1978;61:35-41.
4. Gajdusek DC. Pneumocystis carinii; etiologic agent of interstitial plasma cell pneumonia of premature and young infants. Pediatrics. 1957;19(pt 1):543-565.
5. Gottlieb MS, Schroff R, Schanker HM, et al. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. N Engl J Med. 1981;305:1425-1431.
6. Masur H, Michelis MA, Greene JB, et al. An outbreak of community-acquired Pneumocystis carinii pneumonia: initial manifestation of cellular immune dysfunction. N Engl J Med. 1981;305:1431-1438.
7. Thomas CF, Limper AH. Pneumocystis pneumonia. N Engl J Med. 2004;350:2487-2498.
8. Hughes WT, Rivera GK, Schell MJ, Thornton D, Lott L. Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med. 1987;316:1627-1632.
9. Gebo KA, Fleishman JA, Moore RD. Hospitalizations for metabolic conditions, opportunistic infections, and injection drug use among HIV patients: trends between 1996 and 2000 in 12 states. J Acquir Immune Defic Syndr. 2005;40: 609-616.
10. Maini R, Henderson KL, Sheridan EA, et al. Increasing Pneumocystis pneumonia, England, UK, 2000-2010. Emerg Infect Dis. 2013;19:386-392.
11. Sepkowitz KA, Brown AE, Armstrong D. Pneumocystis carinii pneumonia without acquired immunodeficiency syndrome. More patients, same risk. Arch Intern Med. 1995;155:1125-1128.
12. Hughes WT, Kuhn S, Chaudhary S, et al. Successful chemo-prophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med. 1977;297:1419-1426.
13. Hughes WT, Feldman S, Aur RJA, Verzosa MS, Hustu HO, Simone JV. Intensity of immunosuppressive therapy and the incidence of Pneumocystis carinii pneumonitis. Cancer. 1975; 36:2004-2009.
14. Lindemulder S, Albano E. Successful intermittent prophylaxis with trimethoprim/sulfamethoxazole 2 days per week for Pneumocystis carinii (jiroveci) pneumonia in pediatric oncology patients. Pediatrics. 2007;120:e47-e51.
15. Ohata Y, Ohta H, Hashii Y, Tokimasa S, Ozono K, Hara J. Intermittent oral trimethoprim/sulfamethoxazole on two non-consecutive days per week is effective as Pneumocystis jiroveci pneumonia prophylaxis in pediatric patients receiving chemotherapy or hematopoietic stem cell transplantation. Pediatr Blood Cancer. 2009;52:142-144.
16. Caselli D, Petris MG, Rondelli R, et al. Single-day trimetho-prim/sulfamethoxazole prophylaxis for pneumocystis pneumonia in children with cancer. J Pediatr. 2014;164:389-392.e1.
17. Neumann S, Krause SW, Maschmeyer G, et al. Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematological malignancies and solid tumors: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (D. Ann Hematol. 2013;92:433-442. doi:10.1007/ s00277-013-1698-0.
18. National Comprehensive Cancer Network (NCCN) Guidelines. Prevention and treatment of cancer-related infections. Version 12013.
19. Green H, Paul M, Vidal L, Leibovici L. Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompro-mised patients. Cochrane Database Syst Rev. 2007;3:CD005590.
20. Thomas C, Limper A. Treatment and prevention of Pneumo-cystis pneumonia in non-HIV-infected patients. 2013. Available at: Error! Hyperlink reference not valid.. Accessed September 15, 2013.
21. Haroon M, Phillips R. "There is nothing like looking, if you want to find something"-asking questions and searching for answers-the evidence based approach. Arch Dis Child Educ Pract Ed. 2010;95:34-39.
22. Jaeschke R, Guyatt GH, Dellinger P, et al. Use of GRADE grid to reach decisions on clinical practice guidelines when consensus is elusive. BMJ. 2008;337(jul31-1):a744. Doi:10.1136/bmj.a744.
23. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924-926.
24. Jones J, Hunter D. Qualitative research: consensus methods for medical and health services research. BMJ. 1995;311:376-380.
25. Nelson M, Dockrell D, Edwards S, et al. British HIV Association and British Infection Association guidelines for the treatment of opportunistic infection in HIV-seropositive individuals 2011. HIV Med. 2011;12(suppl 2):1-140.
26. De Vos FY, Gijtenbeek JM, Bleeker-Rovers CP, et al. Pneumocystis jirovecii pneumonia prophylaxis during temozo-lomide treatment for high-grade gliomas. Crit Rev Oncol Hematol. 2013;85:373-382.
27. Mansharamani NG, Balachandran D, Vernovsky I, et al. Peripheral blood CD4+ T-lymphocyte counts during Pneu-mocystis carinii pneumonia in immunocompromised patients without HIV infection. Chest. 2000;118:712-720.
28. Obeid KM, Aguilar J, Szpunar S, et al. Risk factors for Pneumocystis jirovecii pneumonia in patients with lymphoprolifer-ative disorders. Clin Lymphoma Myeloma Leuk. 2012;12:66-69.
29. Overgaard UM, Helweg-Larsen J. Pneumocystis jiroveci pneumonia (PCP) in HIV-1-negative patients: a retrospective study 2002-2004. Scand J Infect Dis. 2007;39:589-595.
30. Catherinot E, Lanternier F, Bougnoux M-E, et al. Pneumo-cystis jirovecii pneumonia. Infect Dis Clin North Am. 2010; 24:107-138.
31. Hughes WT, Price RA, Kim HK, et al. Pneumocystis carinii pneumonitis in children with malignancies. J Pediatr. 1973;82: 404-415.
32. Sepkowitz KA. Pneumocystis carinii pneumonia among patients without AIDS at a cancer hospital. JAMA. 1992;267:832-837.
33. Perera DR, Western KA, Johnson HD, et al. Pneumocystis carinii pneumonia in a hospital for children. Epidemiologic aspects. JAMA. 1970;214:1074-1078.
34. Wilber RB, Feldman S, Malone WJ. Chemoprophylaxis for Pneumocystis carinii pneumonitis. Outcome of unstructured delivery. Am J Dis Child. 1980;134:643-648.
35. Cyklis R, Zielinska A. Pneumocystis carinii infection in children with acute leukemia and non-Hodgkin malignant lymphoma. Pediatr Pol. 1983;58:337-340.
36. Henson JW, Jalaj JK, Walker RW, et al. Pneumocystis carinii pneumonia in patients with primary brain tumors. Arch Neurol. 1991;48:406-409.
37. Sepkowitz KA. Pneumocystis carinii pneumonia in patients without AIDS. Clin Infect Dis. 1993;17(suppl 2):S416-22.
38. Yale SH, Limper AH. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illnesses and prior corticosteroid therapy. Mayo Clin Proc. 1996;71:5-13.
39. Worth LJ, Dooley MJ, Seymour JF, et al. An analysis of the utilisation of chemoprophylaxis against Pneumocystis jirovecii pneumonia in patients with malignancy receiving corticosteroid therapy at a cancer hospital. Br J Cancer. 2005;92:867-872.
40. Neumann S, Krause SW, Maschmeyer G, et al. Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematological malignancies and solid tumors: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (D. Ann Hematol. 2013;92:433-442.
41. Hughes MA, Parisi M, Grossman S, et al. Primary brain tumors treated with steroids and radiotherapy: low CD4 counts and risk of infection. Int J Radiat Oncol Biol Phys. 2005;62:1423-1426.
42. Mathew BS, Grossman SA. Pneumocystis carinii pneumonia prophylaxis in HIV negative patients with primary CNS lymphoma. Cancer Treat Rev. 2003;29:105-119.
43. Grossman SA, Ye X, Lesser G, et al. Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide. Clin Cancer Res. 2011;17:5473-5480.
44. Harris RE, McCallister JA, Allen SA, et al. Prevention of pneumocystis pneumonia. Use of continuous sulfamethoxazole-trimethroprim therapy. Am J Dis Child (1911). 1980;134:35-38.
45. United Kingdom Acute Lymphoblastic Leukaemia and Lymphoma 2011. Available at: www.cancerresearchuk.org/ about-cancer/find-a-clinical-trial/a-trial-looking-treatment-chil dren-young-people-acute-lymphoblastic-leukaemia-lymphoma-ukall-2011. Accessed June 9, 2016.
46. Hughes WT, Feldman S, Sanyal SK. Treatment of Pneumo-cystis carinii pneumonitis with trimethoprim-sulfamethoxazole. Can Med Assoc J. 1975;112:47-50.
47. DeMasi JM, Cox JA, Leonard D, et al. Intravenous pentamidine is safe and effective as primary pneumocystis pneumonia prophylaxis in children and adolescents undergoing hematopoietic stem cell transplantation. Pediatr Infect Dis J. 2013;32:933-936.
48. Kim SY, Dabb AA, Glenn DJ, et al. Intravenous pentamidine is effective as second line Pneumocystis pneumonia prophylaxis in pediatric oncology patients. Pediatr Blood Cancer. 2008;50: 779-783.
49. Mustafa MM, Pappo A, Cash J, et al. Aerosolized pentamidine for the prevention of Pneumocystis carinii pneumonia in children with cancer intolerant or allergic to trimethoprim/ sulfamethoxazole. J Clin Oncol. 1994;12:258-261.
50. Orgel E, Rushing T. Efficacy and tolerability of intravenous pentamidine isethionate for Pneumocystis jiroveci prophylaxis in a pediatric oncology population. Pediatr Infect Dis J. 2014; 33:319-321.
51. Gupta M, Stephenson K, Gauar S, et al. Intravenous pentamidine as an alternate for Pneumocystis carinii pneumonia prophylaxis in children with HIV infection. Pediatr Pulmonol. 1997;23(S16):199-200.
52. Prasad P, Nania JJ, Shankar SM. Pneumocystis pneumonia in children receiving chemotherapy. Pediatr Blood Cancer. 2008; 50:896-898.
53. Esbenshade AJ, Ho RH, Shintani A, et al. Dapsone-induced methemoglobinemia: a dose-related occurrence? Cancer. 2011;117:3485-3492.
54. Colby C, McAfee S, Sackstein R, et al. A prospective randomized trial comparing the toxicity and safety of atovaquone with trimethoprim/sulfamethoxazole as Pneumo-cystis carinii pneumonia prophylaxis following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant. 1999;24:897-902.
55. Ferrazzini G, Klein J, Sulh H, et al. Interaction between trimethoprim-sulfamethoxazole and methotrexate in children with leukemia. J Pediatr. 1990;117:823-826.
56. Relling M, Fairclough D, Ayers D, et al. Patient characteristics associated with high-risk methotrexate concentrations and toxicity. J Clin Oncol. 1994;12:1667-1672.
57. Kovacs GT, Barany O, Schlick B, et al. Late immune recovery in children treated for malignant diseases. Pathol Oncol Res. 2008;14:391-397.
58. Mustafa MM, Buchanan GR, Winick NJ, et al. Immune recovery in children with malignancy after cessation of chemotherapy. J Pediatr Hematol Oncol, 20:451-457.
59. Fontanet A, Chalandon Y, Roosnek E, et al. Cotrimoxazole myelotoxicity in hematopoietic SCT recipients: time for reappraisal. Bone Marrow Transplant. 2011;46:1272-1273.
60. Masters PA. Trimethoprim-sulfamethoxazole revisited. Arch Intern Med. 2003;163:402-410.
61. Huovinen P. Increases in rates of resistance to trimethoprim. Clin Infect Dis. 1997;24(suppl 1):S63-S66.
62. Martin JN, Rose DA, Hadley WK, et al. Emergence of trimethoprim-sulfamethoxazole resistance in the AIDS era. J Infect Dis. 1999;180:1809-1818.
63. Fox BC, Sollinger HW, Belzer FO, et al. A prospective, randomized, double-blind study of trimethoprim-sulfamethoxazole for prophylaxis of infection in renal transplantation: clinical efficacy, absorption of trimethoprim-sulfamethoxazole, effects on the micro-flora, and the cost-benefit of prophy. Am J Med. 1990;89: 255-274.
64. Queener SF, Cody V, Pace J, Torkelson P, Gangjee A. Trimethoprim resistance of dihydrofolate reductase (DHFR) variants from clinical isolates of Pneumocystis jirovecii. Anti-microb Agents Chemother. 2013:574990-4998.
65. Nahimana A, Rabodonirina M, Bille J, et al. Mutations of Pneumocystis jirovecii dihydrofolate reductase associated with failure of prophylaxis. Antimicrob Agents Chemother. 2004; 48:4301-4305.
66. British National Formulary for Children. 2016. Available at: www.evidence.nhs.uk/formulary/bnfc/current. Accessed February 12, 2016.
67. Brown RJ, Rahim H, Wong KE, et al. Infectious complications in the first year following autologous hematopoietic progenitor cell rescue for children with brain tumors. Pediatr Blood Cancer. 2013;60:2012-2017.
68. Peters SG, Prakash UB. Pneumocystis carinii pneumonia. Review of 53 cases. Am J Med. 1987;82:73-78.
69. Sedaghatian MR, Singer DB. Pneumocystis carinii in children with malignant disease. Cancer. 1972;29:772-777.
70. DeMasi J, Cox J, Koh A, Aquino VM. Safety and efficacy of intravenous pentamidine in children and adolescents undergoing hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2012;2:S321.
71. Madden RM, Pui C-H, Hughes WT, et al. Prophylaxis of Pneumocystis carinii pneumonia with atovaquone in children with leukemia. Cancer. 2007;109:1654-1658.
72. Guyatt GH, Oxman AD, Kunz R, et al. What is "quality of evidence" and why is it important to clinicians? BMJ. 2008;336:995-998.
73. Guyatt GH, Oxman AD, Kunz R, et al. Going from evidence to recommendations. BMJ. 2008;336:1049-1051.
74. Shea BJ, Grimshaw JM, Wells GA, et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol. 2007;7:10. Doi:10.1186/1471-2288-7-10.